iShares(R) Nasdaq Biotechnology Index Fund and iShares S&P 100 Index Fund Complete Move to New Listing Exchanges

Market Wire, September, 2008

Barclays Global Investors (BGI), one of the world's largest institutional asset managers and Exchange Traded Funds (ETF) managers, announced today the successful transfer of the iShares Nasdaq Biotechnology Index Fund (ticker: IBB) from the American Stock Exchange to The NASDAQ Stock Market and the iShares S&P 100 Index Fund (ticker: OEF) from the Chicago Board Options Exchange to the NYSE Arca listing and trading platform. Current shareholders are not required to take any actions as a result of these changes.

The iShares Funds are index funds that are bought and sold like common stocks on securities exchanges. The iShares Funds are attractive to many individual and institutional investors and financial intermediaries because of their relative low cost, tax efficiency and trading flexibility. Investors can purchase and sell shares through any brokerage firm, financial advisor, or online broker, and hold the funds in any type of brokerage account.

Carefully consider the Funds' investment objectives, risk factors and charges and expenses before investing. This and other information can be found in the Funds' prospectuses, which may be obtained by calling 1-800-iShares or by visiting www.ishares.com . Read the prospectus carefully before investing.

About Barclays Global Investors

Barclays Global Investors is one of the world's largest asset managers and a leading global provider of investment management products and services with more than 2,900 institutional clients and in excess of $2.0 trillion of assets under management as of December 31, 2007. BGI transformed the investment industry by creating the first index strategy in 1971 and the first quantitative active strategy in 1979. BGI is the global product leader in exchange traded funds (iShares® exchange traded funds) with over 320 funds for institutions and individuals globally.

Investing involves risks, including possible loss of principal. Transactions in shares of the iShares Funds will result in brokerage commissions.

The iShares Funds ("Funds") are distributed by SEI Investments Distribution Co. (SEI). Barclays Global Fund Advisors (BGFA) serves as an advisor to the Funds. BGFA is a subsidiary of Barclays Global Investors, N.A., a majority-owned subsidiary of Barclays Bank PLC, none of which is affiliated with SEI.

The iShares Funds are not sponsored, endorsed, issued, sold or promoted by The NASDAQ Stock Market, Inc. or Standard and Poor's. Neither of these companies make any representation regarding the advisability of investing in the Funds. Neither SEI nor BGI, nor any of their affiliates, are affiliated with the companies listed above.

NASDAQ® and NASDAQ Biotechnology Index® are registered trademarks of The NASDAQ OMX Group, Inc. (which with its affiliates and subsidiaries is collectively "NASDAQ OMX") and are licensed for use by Barclays Global Investors. The iShares NASDAQ Biotechnology Fund has not been passed on by NASDAQ OMX as to its legality or suitability. The iShares NASDAQ Biotechnology Fund is not issued, endorsed, sold, or promoted by NASDAQ OMX. NASDAQ OMX MAKES NO WARRANTIES AND BEARS NO LIABILITY WITH RESPECT TO THE iShares NASDAQ Biotechnology Fund.

©2008 Barclays Global Investors, N.A. All rights reserved. iShares® is a registered trademark of Barclays Global Investors, N.A. All other trademarks, servicemarks or registered trademarks are the property of their respective owners.